HOME >> BIOLOGY >> NEWS
Endometriosis: Could angiostatic therapy be the new treatment of the future?

Berlin, Germany: Chemicals that inhibit the development of new blood vessels could prove to be a new way of treating endometriosis, according to research from The Netherlands and the USA presented today (Monday 28 June) at the 20th annual meeting of the European Society of Human Reproduction and Embryology.

However, the researchers warned that the work is still at an early stage, with the current investigations taking place in mice, so it would be a few years before the findings could translate into improved treatments for women with the disease.

Endometriosis is a disease of the lining tissue of the womb. It can be very painful and can have a serious impact on the lives of women. At present, there is no satisfactory treatment or cure for the condition, which affects between 10-25% of women of reproductive age1.

Annemiek Nap, a doctor at the University Hospital Maastricht, The Netherlands, told the conference that she and her colleagues tested whether angiostatic therapy (therapy that inhibits the development of blood vessels) could prevent new endometriosis lesions growing and whether it could interfere with the maintenance and growth of existing lesions.

They used four angiostatic compounds: anti-human vascular endothelial growth factor (anti-hVGF), TNP-470, endostatin and anginex. They tested the compounds on human endometrium that had been transplanted into 49 mice and allowed to grow into endometriotic lesions. "We thought that using human endometrium would make the model as close to the human situation as possible," said Ms Nap.

"We found that angiostatic therapy inhibits the number of newly developed blood vessels around lesions. However, the mature vessels, which are protected by smooth muscle cells, were not inhibited. We also observed that the number of endometriotic lesions in mice treated with angiostatic agents was lower than the number of endometriotic lesions in mice not treated with angiostatic agents."
'"/>

Contact: Mary Rice
mary.rice@blueprintpartners.be
European Society for Human Reproduction and Embryology
28-Jun-2004


Page: 1 2 3

Related biology news :

1. Could mice hold the secret to longer life?
2. Could vitamins raise levels of bad cholesterol? Animal study suggests they might
3. Could memory performance and spatial learning be genetically based?
4. Could a specific protein contribute to erectile dysfunction for the diabetic and obese?
5. Could diabetes treatments fight cancer?
6. Could rice be the source for a natural herbicide?
7. Could hibernators hold the key to improving organ preservation?
8. Could Bt transgenic crops have nutritionally favourable effects on insects?
9. Could one less cookie a day help the fight against fat?
10. Could an anti-marijuana compound hold the key to body weight and appetite control?
11. Study finds genetic aberrations linked to lung cancer; Could help in early diagnosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
Breaking Biology Technology:
Cached News: